United Therapeutics (UTHR) Stock
Lung disease drug maker funding organ transplant research. Here's the price, business snapshot, and what's worth knowing about United Therapeutics in August 2026.
United Therapeutics Corporation (UTHR) is a US-based biotechnology company focused on therapies for pulmonary arterial hypertension (PAH) and related rare diseases. It markets prostacyclin-class and inhaled therapies across intravenous, oral and inhalation routes, generating recurring revenues from long-term treatments. The company also invests heavily in organ manufacturing and regenerative medicine — including xenotransplantation and bioengineered-lung research — targeting chronic transplant shortages. Its financial profile blends cash-generating marketed drugs with high-risk, high-reward R&D programmes. Key considerations for investors include clinical trial outcomes, regulatory approvals, pricing and reimbursement dynamics, and patent lifecycles. Market capitalisation is around $19.11 billion, reflecting both existing product cash flows and longer-term innovation hopes. This summary aims to inform and educate; it is not personalised investment advice. Values can fall as well as rise, and prospective investors should consider their own risk tolerance and seek independent advice where appropriate.
Why It’s Moving
UTHR steadies on pipeline progress as investors weigh earnings strength against softer revenue growth
- Second-quarter results showed earnings beat estimates while revenue came in below expectations, highlighting strong profitability even as top-line momentum softened.
- Management pointed to major pipeline progress, including positive late-stage trial data and new FDA submissions, which keeps the growth story tied to future approvals rather than near-term sales.
- A fresh update on August 17 confirmed full enrollment in the TETON-PPF study, reinforcing investor focus on the company’s pulmonary fibrosis program and longer-term pipeline catalysts.
UTHR steadies on pipeline progress as investors weigh earnings strength against softer revenue growth
- Second-quarter results showed earnings beat estimates while revenue came in below expectations, highlighting strong profitability even as top-line momentum softened.
- Management pointed to major pipeline progress, including positive late-stage trial data and new FDA submissions, which keeps the growth story tied to future approvals rather than near-term sales.
- A fresh update on August 17 confirmed full enrollment in the TETON-PPF study, reinforcing investor focus on the company’s pulmonary fibrosis program and longer-term pipeline catalysts.
Sixth Month Growth Performance
When is the next earnings date for UNITED THERAPEUTICS CORP (UTHR)?
The next earnings date for UTHR is estimated for November 4, 2026, and it should cover Q3 2026. This follows the company’s typical late-October to early-November reporting pattern after its Q2 2026 release on August 5, 2026. The date is an estimate rather than a confirmed company announcement.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying United Therapeutics' stock despite its current price being higher than the target.
Financial Health
United Therapeutics is performing well with strong profit margins and healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pulmonary therapies
Established PAH medicines provide recurring revenue and clinical data; watch trial readouts and competition, though outcomes can vary.
Organ manufacturing
Work on xenotransplantation and bioengineered lungs targets a major unmet need, but timelines and regulatory paths are long and uncertain.
Commercial footing
A largely US-driven revenue base with growing international reach; pricing, patents and reimbursement will shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
